The scenario is rapidly evolving after the investigation of tucatinib in the HER2CLIMB trial on HER2+ metastatic BC, which displayed superiority in all the planned outcomes, such as PFS, OS, objective response rate [36] and quality of life [37] including in patients with BM [38]. Here, ERBB2 is linked to breast cancer.